FDA Modernization Act 2.0

The U.S. Congress recently passed the FDA Modernization Act 2.01 which permits the use of alternatives to animal studies as part of the FDA’s regulatory approval process. The new legislation explicitly identifies in silico models as one of these alternatives. This legislation is an important step forward in the use of alternative methods and will …

The Use of Artificial Intelligence to Support Safety Predictions

Last year, we were happy to contribute to a new book describing the use of both supervised and unsupervised machine learning approaches to support the prediction of toxicity and is illustrated with case studies related to regulatory submissions. The book chapter emphasized the importance of high-quality databases, containing toxicology and chemistry information. Such comprehensive databases …

Computational toxicology 2022 year-end review

The computational toxicology group here at Instem has had another busy year that has resulted in six publications and book chapters1-6, completion of existing and initiation of new collaborative working groups, as well as significant updates to our computational toxicology solutions. We have been collaborating on a number of research topics related to the in …

Update on the Mutamind N-nitrosamine project

Earlier this year, it was announced that Instem was part of the Mutamind industry and academic consortium of 9 beneficiaries, funded by EMA and led by Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)1. Instem is collaborating on this 2-year research project to further investigate the mutagenicity of different classes of N-nitrosamines to distinguish highly …

New paper discussing the assessment of abuse liability using blood-brain barrier QSAR models

Last year, we discussed the development of a new solution to support the assessment of abuse liability.1 This included a large database of over 4,000 chemicals from numerous sources including the US Drug Enforcement Agency (DEA) scheduled drugs and structural alerts to profile potential abuse liability. This assessment has now been extended to include a …

November 2022 computational toxicology conferences

We have been busy preparing for a number of upcoming conferences in November1. At the 2nd International Akademie Fresenius Gene-Tox Conference (November 3, 2022), Kevin Cross will discuss “N-Nitrosamine Impurities in Drugs – Introducing the EMA-Mutamind Project”. As part of the Extractables & Leachables Europe 2022 Conference (November 7 – 8, 2022) Glenn Myatt will …

Acute Toxicity in silico Battery

We are happy to have completed, after many years of work, a full battery of in silico models to evaluate acute toxicity. These models predict acute lethality by three routes of exposure (oral, dermal, inhalation), as well as skin and eye irritation/corrosion, and skin sensitization. They aim to support a variety of applications, including health, …

New read-across tool

Over the last year we have been working hard developing a new easy-to-use read-across solution that can instantaneously access over 200,000 chemicals with over 600,000 toxicity studies. The platform is able to integrate this data with chemicals and studies added by the user to conduct a read-across evaluation. It has been designed to directly support …

ELSIE Webinar on a Framework for Sensitization Assessment for E&L and Practical Application

We are delighted to be participating in an upcoming webinar organized by the Extractables and Leachables Safety Information Exchange (ELSIE) Consortium on the topic of a framework for sensitization assessment for Extractables and Leachables (E&L) on 22 September 2022, 9:30 – 11:00 AM ET1. We will be describing the development of a representative database of …

New paper on the use of the Ames assay to predict carcinogenicity of N-Nitrosamines

This week, we are pleased to welcome Dr. Kevin P. Cross, Instem’s Principal Investigator with U.S. FDA Collaborations and VP of Product Engineering and Production, as a guest contributor to the blog. We were happy to contribute to a recent publication titled “Use of the Bacterial Reverse Mutation Assay to Predict Carcinogenicity of N-Nitrosamines”.1 N-Nitrosamines …